Genesis No Public Human Trials

The main issue is not whether Genesis can design promising molecules on a benchmark, it is whether the company can prove that its design engine produces drugs that survive the brutal handoff from computer to animal studies to human patients. As of September 2026, Genesis still had no public human trial, while peers had already crossed that line with named clinical assets, which matters because pharma buyers reward platforms that have shown real patient translation, not just better model scores.

• Genesis runs a tight loop of model, synthesis, and wet lab testing, but its disclosed internal assets were still before the clinic, including a pan mutant allosteric PIK3CA program that was only nearing development candidate nomination. That means the public proof point remains preclinical.
  1 sacra 2 sacra
• Iambic and Insilico have already turned AI discovery into human dosing. Iambic lists IAM1363 in Phase 1 and Insilico started Phase III dosing for rentosertib in IPF in September 2026. Those milestones make their platforms easier for partners to underwrite because the compounds have cleared real regulatory and clinical gates.
  3 iambic 4 insilico
• Recursion and Schrödinger show two other ways this market is maturing. Recursion says it now has five clinical stage programs after combining with Exscientia, while Schrödinger reports more than ten clinical stage assets across its portfolio. Both have moved beyond selling discovery software alone and are using clinical progress to deepen platform credibility.
  5 recursion 6 schrodinger

The next leg of competition is likely to shift from who predicts binding best, to who can repeatedly move AI designed molecules into INDs and then through early human data. For Genesis, the highest value milestone is no longer another benchmark win, it is a first clinical asset that proves GEMS can create compounds worth carrying into patients.